The DOI matches its Crossref record; 137 of the 137 references it cites were found in a registry or an index.
Mechanisms of Sensitivity and Resistance to CDK4/6 Inhibition
Open accessAbstract
Inhibiting the cell-cycle kinases CDK4 and CDK6 results in significant therapeutic effect in patients with advanced hormone-positive breast cancer. The efficacy of this strategy is, however, limited by innate or acquired resistance mechanisms and its application to other tumor types is still uncertain. Here, through an integrative analysis of sensitivity and resistance mechanisms, we discuss the use of CDK4/6 inhibitors in combination with available targeted therapies, immunotherapy, or classical chemotherapy with the aim of improving future therapeutic uses of CDK4/6 inhibition in a variety of cancers.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Cell cycle, CDKs and cancer: a changing paradigm
Malumbres, M., & Barbacid, M. (2009) · Nature Reviews Cancer · doi:10.1038/nrc2602 · Cited by 3,957
Self-citationSuper-enhancers in the control of cell identity and disease
Hnisz, D., Abraham, B. J., Lee, T. I., Lau, A., Saint-André, V., Sigova, A. A., Hoke, H. A., & Young, R. A. (2013) · Cell · doi:10.1016/j.cell.2013.09.053 · Cited by 3,662
Palbociclib and letrozole in advanced breast cancer
Finn, R. S., Martin, M., Rugo, H. S., Jones, S., Im, S.-A., Gelmon, K., Harbeck, N., Lipatov, O. N., Walshe, J. M., Moulder, S., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1607303 · Cited by 3,007
Ribociclib as first-line therapy for HR-positive, advanced breast cancer
Hortobagyi, G. N., Stemmer, S. M., Burris, H. A., Yap, Y.-S., Sonke, G. S., Paluch-Shimon, S., Campone, M., Blackwell, K. L., André, F., Winer, E. P., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1609709 · Cited by 2,039
Sherr, C. J. (1993) · Cell · doi:10.1016/0092-8674(93)90636-5 · Cited by 1,960
The history and future of targeting cyclin-dependent kinases in cancer therapy
Asghar, U., Witkiewicz, A. K., Turner, N. C., & Knudsen, E. S. (2015) · Nature Reviews Drug Discovery · doi:10.1038/nrd4504 · Cited by 1,767
Sledge, G. W., Toi, M., Neven, P., Sohn, J., Inoue, K., Pivot, X., Burdaeva, O., Okera, M., Masuda, N., Kaufman, P. A., et al. (2017) · Journal of Clinical Oncology · doi:10.1200/jco.2017.73.7585 · Cited by 1,680
Malumbres, M. (2014) · Genome Biology · doi:10.1186/gb4184 · Cited by 1,654
Self-citationCDK4/6 inhibition triggers anti-tumour immunity
Goel, S., DeCristo, M. J., Watt, A. C., BrinJones, H., Sceneay, J., Li, B. B., Khan, N., Ubellacker, J. M., Xie, S., Metzger-Filho, O., et al. (2017) · Nature · doi:10.1038/nature23465 · Cited by 1,513
To cycle or not to cycle: a critical decision in cancer
Malumbres, M., & Barbacid, M. (2001) · Nature Reviews Cancer · doi:10.1038/35106065 · Cited by 1,468
Self-citationA Cancer Cell Program Promotes T Cell Exclusion and Resistance to Checkpoint Blockade
Jerby-Arnon, L., Shah, P., Cuoco, M. S., Rodman, C., Su, M.-J., Melms, J. C., Leeson, R., Kanodia, A., Mei, S., Lin, J.-R., et al. (2018) · Cell · doi:10.1016/j.cell.2018.09.006 · Cited by 1,429
Finn, R. S., Dering, J., Conklin, D., Kalous, O., Cohen, D. J., Desai, A. J., Ginther, C., Atefi, M., Chen, I., Fowst, C., et al. (2009) · Breast Cancer Research · doi:10.1186/bcr2419 · Cited by 1,398
Fry, D. W., Harvey, P. J., Keller, P. R., Elliott, W. L., Meade, M., Trachet, E., Albassam, M., Zheng, X., Leopold, W. R., Pryer, N. K., et al. (2004) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.1427.3.11 · Cited by 1,236
Treating cancer with selective CDK4/6 inhibitors
O'Leary, B., Finn, R. S., & Turner, N. C. (2016) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2016.26 · Cited by 1,137
Cdk1 is sufficient to drive the mammalian cell cycle
Santamaría, D., Barrière, C., Cerqueira, A., Hunt, S., Tardy, C., Newton, K., Cáceres, J. F., Dubus, P., Malumbres, M., & Barbacid, M. (2007) · Nature · doi:10.1038/nature06046 · Cited by 1,114
Self-citationCyclin D1 provides a link between development and oncogenesis in the retina and breast
Sicinski, P., Donaher, J. L., Parker, S. B., Li, T., Fazeli, A., Gardner, H., Haslam, S. Z., Bronson, R. T., Elledge, S. J., & Weinberg, R. A. (1995) · Cell · doi:10.1016/0092-8674(95)90034-9 · Cited by 1,021
Cyclin D–CDK4 kinase destabilizes PD-L1 via cullin 3–SPOP to control cancer immune surveillance
Zhang, J., Bu, X., Wang, H., Zhu, Y., Geng, Y., Nihira, N. T., Tan, Y., Ci, Y., Wu, F., Dai, X., et al. (2018) · Nature · doi:10.1038/nature25015 · Cited by 1,013
Overall survival with ribociclib plus endocrine therapy in breast cancer
Im, S.-A., Lu, Y.-S., Bardia, A., Harbeck, N., Colleoni, M., Franke, F., Chow, L., Sohn, J., Lee, K.-S., Campos-Gomez, S., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1903765 · Cited by 1,001
Specific protection against breast cancers by cyclin D1 ablation
Yu, Q., Geng, Y., & Sicinski, P. (2001) · Nature · doi:10.1038/35082500 · Cited by 934
CDK4/6 Inhibition Augments Antitumor Immunity by Enhancing T-cell Activation
Deng, J., Wang, E. S., Jenkins, R. W., Li, S., Dries, R., Yates, K., Chhabra, S., Huang, W., Liu, H., Aref, A. R., et al. (2018) · Cancer Discovery · doi:10.1158/2159-8290.cd-17-0915 · Cited by 770
Herrera-Abreu, M. T., Palafox, M., Asghar, U., Rivas, M. A., Cutts, R. J., Garcia-Murillas, I., Pearson, A., Guzman, M., Rodriguez, O., Grueso, J., et al. (2016) · Cancer Research · doi:10.1158/0008-5472.can-15-0728 · Cited by 762
Patnaik, A., Rosen, L. S., Tolaney, S. M., Tolcher, A. W., Goldman, J. W., Gandhi, L., Papadopoulos, K. P., Beeram, M., Rasco, D. W., Hilton, J. F., et al. (2016) · Cancer Discovery · doi:10.1158/2159-8290.cd-16-0095 · Cited by 743
Plasma ESR1 Mutations and the Treatment of Estrogen Receptor–Positive Advanced Breast Cancer
Fribbens, C., O’Leary, B., Kilburn, L., Hrebien, S., Garcia-Murillas, I., Beaney, M., Cristofanilli, M., Andre, F., Loi, S., Loibl, S., et al. (2016) · Journal of Clinical Oncology · doi:10.1200/jco.2016.67.3061 · Cited by 722
Spencer, S. L., Cappell, S. D., Tsai, F.-C., Overton, K. W., Wang, C. L., & Meyer, T. (2013) · Cell · doi:10.1016/j.cell.2013.08.062 · Cited by 698
Mice lacking cyclin D1 are small and show defects in eye and mammary gland development.
Fantl, V, Stamp, G., Andrews, A., Rosewell, I., & Dickson, C. (1995) · Genes & Development · doi:10.1101/gad.9.19.2364 · Cited by 691
Dickler, M. N., Tolaney, S. M., Rugo, H. S., Cortés, J., Diéras, V., Patt, D., Wildiers, H., Hudis, C. A., O'Shaughnessy, J., Zamora, E., et al. (2017) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-17-0754 · Cited by 676
O'Leary, B., Cutts, R. J., Liu, Y., Hrebien, S., Huang, X., Fenwick, K., André, F., Loibl, S., Loi, S., Garcia-Murillas, I., et al. (2018) · Cancer Discovery · doi:10.1158/2159-8290.cd-18-0264 · Cited by 650
Gelbert, L. M., Cai, S., Lin, X., Sanchez-Martinez, C., del Prado, M., Lallena, M. J., Torres, R., Ajamie, R. T., Wishart, G. N., Flack, R. S., et al. (2014) · Investigational New Drugs · doi:10.1007/s10637-014-0120-7 · Cited by 577
Anders, L., Ke, N., Hydbring, P., Choi, Y. J., Widlund, H. R., Chick, J. M., Zhai, H., Vidal, M., Gygi, S. P., Braun, P., et al. (2011) · Cancer Cell · doi:10.1016/j.ccr.2011.10.001 · Cited by 543
Non-canonical functions of cell cycle cyclins and cyclin-dependent kinases
Hydbring, P., Malumbres, M., & Sicinski, P. (2016) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm.2016.27 · Cited by 528
Self-citationLoss of the FAT1 Tumor Suppressor Promotes Resistance to CDK4/6 Inhibitors via the Hippo Pathway
Li, Z., Razavi, P., Li, Q., Toy, W., Liu, B., Ping, C., Hsieh, W., Sanchez-Vega, F., Brown, D. N., Da Cruz Paula, A. F., et al. (2018) · Cancer Cell · doi:10.1016/j.ccell.2018.11.006 · Cited by 508
Overcoming Therapeutic Resistance in HER2-Positive Breast Cancers with CDK4/6 Inhibitors
Goel, S., Wang, Q., Watt, A. C., Tolaney, S. M., Dillon, D. A., Li, W., Ramm, S., Palmer, A. C., Yuzugullu, H., Varadan, V., et al. (2016) · Cancer Cell · doi:10.1016/j.ccell.2016.02.006 · Cited by 470
Schaer, D. A., Beckmann, R. P., Dempsey, J. A., Huber, L., Forest, A., Amaladas, N., Li, Y., Wang, Y. C., Rasmussen, E. R., Chin, D., et al. (2018) · Cell Reports · doi:10.1016/j.celrep.2018.02.053 · Cited by 469
Turner, N. C., Liu, Y., Zhu, Z., Loi, S., Colleoni, M., Loibl, S., DeMichele, A., Harbeck, N., André, F., Bayar, M. A., et al. (2019) · Journal of Clinical Oncology · doi:10.1200/jco.18.00925 · Cited by 449
CDK 4/6 inhibitors sensitize PIK3CA mutant breast cancer to PI3K inhibitors
Vora, S. R., Juric, D., Kim, N., Mino-Kenudson, M., Huynh, T., Costa, C., Lockerman, E. L., Pollack, S. F., Liu, M., Li, X., et al. (2014) · Cancer Cell · doi:10.1016/j.ccr.2014.05.020 · Cited by 438
Requirement for CDK4 kinase function in breast cancer
Yu, Q., Sicinska, E., Geng, Y., Ahnström, M., Zagozdzon, A., Kong, Y., Gardner, H., Kiyokawa, H., Harris, L. N., Stål, O., et al. (2006) · Cancer Cell · doi:10.1016/j.ccr.2005.12.012 · Cited by 429
Wander, S. A., Cohen, O., Gong, X., Johnson, G. N., Buendia-Buendia, J. E., Lloyd, M. R., Kim, D., Luo, F., Mao, P., Helvie, K., et al. (2020) · Cancer Discovery · doi:10.1158/2159-8290.cd-19-1390 · Cited by 429
Puyol, M., Martín, A., Dubus, P., Mulero, F., Pizcueta, P., Khan, G., Guerra, C., Santamaría, D., & Barbacid, M. (2010) · Cancer Cell · doi:10.1016/j.ccr.2010.05.025 · Cited by 415
Yang, C., Li, Z., Bhatt, T., Dickler, M., Giri, D., Scaltriti, M., Baselga, J., Rosen, N., & Chandarlapaty, S. (2017) · Oncogene · doi:10.1038/onc.2016.379 · Cited by 415
Aberrant FGFR signaling mediates resistance to CDK4/6 inhibitors in ER+ breast cancer
Formisano, L., Lu, Y., Servetto, A., Hanker, A. B., Jansen, V. M., Bauer, J. A., Sudhan, D. R., Guerrero-Zotano, A. L., Croessmann, S., Guo, Y., et al. (2019) · Nature Communications · doi:10.1038/s41467-019-09068-2 · Cited by 408
Dual CDK4/CDK6 Inhibition Induces Cell-Cycle Arrest and Senescence in Neuroblastoma
Rader, J., Russell, M. R., Hart, L. S., Nakazawa, M. S., Belcastro, L. T., Martinez, D., Li, Y., Carpenter, E. L., Attiyeh, E. F., Diskin, S. J., et al. (2013) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-13-1675 · Cited by 394
Condorelli, R., Spring, L., O’Shaughnessy, J., Lacroix, L., Bailleux, C., Scott, V., Dubois, J., Nagy, R. J., Lanman, R. B., Iafrate, A. J., et al. (2018) · Annals of Oncology · doi:10.1093/annonc/mdx784 · Cited by 394
Cdc2–cyclin E complexes regulate the G1/S phase transition
Aleem, E., Kiyokawa, H., & Kaldis, P. (2005) · Nature Cell Biology · doi:10.1038/ncb1284 · Cited by 383
Molecular mechanisms of resistance to CDK4/6 inhibitors in breast cancer: A review
Pandey, K., An, H., Kim, S. K., Lee, S. A., Kim, S., Lim, S. M., Kim, G. M., Sohn, J., & Moon, Y. W. (2019) · International Journal of Cancer · doi:10.1002/ijc.32020 · Cited by 361
The metabolic function of cyclin D3-CDK6 kinase in cancer cell survival
Wang, H., Nicolay, B. N., Chick, J. M., Gao, X., Geng, Y., Ren, H., Gao, H., Yang, G., Williams, J. A., Suski, J. M., et al. (2017) · Nature · doi:10.1038/nature22797 · Cited by 347
The Requirement for Cyclin D Function in Tumor Maintenance
Choi, Y. J., Li, X., Hydbring, P., Sanda, T., Stefano, J., Christie, A. L., Signoretti, S., Look, A. T., Kung, A. L., von Boehmer, H., et al. (2012) · Cancer Cell · doi:10.1016/j.ccr.2012.09.015 · Cited by 342
Reciprocal Rb inactivation and p16INK4 expression in primary lung cancers and cell lines.
Shapiro, G. I., Edwards, C. D., Kobzik, L., Godleski, J. J., Richards, W. G., Sugarbaker, D. J., & Rollins, B. J. (1995) · PubMed · Cited by 340
Rescue of Cyclin D1 Deficiency by Knockin Cyclin E
Geng, Y., Whoriskey, W., Park, M. Y., Bronson, R. T., Medema, R. H., Li, T., Weinberg, R. A., & Sicinski, P. (1999) · Cell · doi:10.1016/s0092-8674(00)80788-6 · Cited by 336
Cyclin D1-dependent kinase activity in murine development and mammary tumorigenesis
Landis, M. W., Pawlyk, B. S., Li, T., Sicinski, P., & Hinds, P. W. (2006) · Cancer Cell · doi:10.1016/j.ccr.2005.12.019 · Cited by 329
A Kinase-Independent Function of CDK6 Links the Cell Cycle to Tumor Angiogenesis
Kollmann, K., Heller, G., Schneckenleithner, C., Warsch, W., Scheicher, R., Ott, R. G., Schäfer, M., Fajmann, S., Schlederer, M., Schiefer, A.-I., et al. (2013) · Cancer Cell · doi:10.1016/j.ccr.2013.07.012 · Cited by 313
Self-citationVijayaraghavan, S., Karakas, C., Doostan, I., Chen, X., Bui, T., Yi, M., Raghavendra, A. S., Zhao, Y., Bashour, S. I., Ibrahim, N. K., et al. (2017) · Nature Communications · doi:10.1038/ncomms15916 · Cited by 292
PTEN Loss Mediates Clinical Cross-Resistance to CDK4/6 and PI3Kα Inhibitors in Breast Cancer
Costa, C., Wang, Y., Ly, A., Hosono, Y., Murchie, E., Walmsley, C. S., Huynh, T., Healy, C., Peterson, R., Yanase, S., et al. (2020) · Cancer Discovery · doi:10.1158/2159-8290.cd-18-0830 · Cited by 270
Fueling the Cell Division Cycle
Salazar-Roa, M., & Malumbres, M. (2017) · Trends in Cell Biology · doi:10.1016/j.tcb.2016.08.009 · Cited by 268
Self-citationPhosphorylated RB Promotes Cancer Immunity by Inhibiting NF-κB Activation and PD-L1 Expression
Jin, X., Ding, D., Yan, Y., Li, H., Wang, B., Ma, L., Ye, Z., Ma, T., Wu, Q., Rodrigues, D. N., et al. (2019) · Molecular Cell · doi:10.1016/j.molcel.2018.10.034 · Cited by 257
Tripathy, D., Bardia, A., & Sellers, W. R. (2017) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-16-3157 · Cited by 247
Jansen, V. M., Bhola, N. E., Bauer, J. A., Formisano, L., Lee, K.-M., Hutchinson, K. E., Witkiewicz, A. K., Moore, P. D., Estrada, M. V., Sánchez, V., et al. (2017) · Cancer Research · doi:10.1158/0008-5472.can-16-2653 · Cited by 244
Gong, X., Litchfield, L. M., Webster, Y., Chio, L.-C., Wong, S. S., Stewart, T. R., Dowless, M., Dempsey, J., Zeng, Y., Torres, R., et al. (2017) · Cancer Cell · doi:10.1016/j.ccell.2017.11.006 · Cited by 236
Aurora A Kinase Inhibition Is Synthetic Lethal with Loss of the RB1 Tumor Suppressor Gene
Gong, X., Du, J., Parsons, S. H., Merzoug, F. F., Webster, Y., Iversen, P. W., Chio, L.-C., Van Horn, R. D., Lin, X., Blosser, W., et al. (2019) · Cancer Discovery · doi:10.1158/2159-8290.cd-18-0469 · Cited by 235
Nayar, U., Cohen, O., Kapstad, C., Cuoco, M. S., Waks, A. G., Wander, S. A., Painter, C., Freeman, S., Persky, N. S., Marini, L., et al. (2019) · Nature Genetics · doi:10.1038/s41588-018-0287-5 · Cited by 230
p27 allosterically activates cyclin-dependent kinase 4 and antagonizes palbociclib inhibition
Guiley, K. Z., Stevenson, J. W., Lou, K., Barkovich, K. J., Kumarasamy, V., Wijeratne, T. U., Bunch, K. L., Tripathi, S., Knudsen, E. S., Witkiewicz, A. K., et al. (2019) · Science · doi:10.1126/science.aaw2106 · Cited by 229
Dean, J. L., McClendon, A. K., Hickey, T. E., Butler, L. M., Tilley, W. D., Witkiewicz, A. K., & Knudsen, E. S. (2012) · Cell Cycle · doi:10.4161/cc.21195 · Cited by 226
Tigan, A.-S., Bellutti, F., Kollmann, K., Tebb, G., & Sexl, V (2016) · Oncogene · doi:10.1038/onc.2015.407 · Cited by 204
Finn, R. S., Liu, Y., Zhu, Z., Martin, M., Rugo, H. S., Diéras, V., Im, S.-A., Gelmon, K. A., Harbeck, N., Lu, D. R., et al. (2020) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-19-0751 · Cited by 201
A Centrosomal Localization Signal in Cyclin E Required for Cdk2-Independent S Phase Entry
Matsumoto, Y., & Maller, J. L. (2004) · Science · doi:10.1126/science.1103544 · Cited by 200
Combined CDK4/6 and PI3Kα Inhibition Is Synergistic and Immunogenic in Triple-Negative Breast Cancer
Teo, Z. L., Versaci, S., Dushyanthen, S., Caramia, F., Savas, P., Mintoff, C. P., Zethoven, M., Virassamy, B., Luen, S. J., McArthur, G. A., et al. (2017) · Cancer Research · doi:10.1158/0008-5472.can-17-2210 · Cited by 196
Cen, L., Carlson, B. L., Schroeder, M. A., Ostrem, J. L., Kitange, G. J., Mladek, A. C., Fink, S. R., Decker, P. A., Wu, W., Kim, J.-S., et al. (2012) · Neuro-Oncology · doi:10.1093/neuonc/nos114 · Cited by 189
Kinase-independent function of cyclin E
Geng, Y., Lee, Y.-M., Welcker, M., Swanger, J., Zagozdzon, A., Winer, J. D., Roberts, J. M., Kaldis, P., Clurman, B. E., & Sicinski, P. (2007) · Molecular Cell · doi:10.1016/j.molcel.2006.11.029 · Cited by 187
Therapeutic Targeting of the Cyclin D3:CDK4/6 Complex in T Cell Leukemia
Sawai, C. M., Freund, J., Oh, P., Ndiaye-Lobry, D., Bretz, J. C., Strikoudis, A., Genesca, L., Trimarchi, T., Kelliher, M. A., Clark, M., et al. (2012) · Cancer Cell · doi:10.1016/j.ccr.2012.09.016 · Cited by 183
Michaloglou, C., Crafter, C., Siersbaek, R., Delpuech, O., Curwen, J. O., Carnevalli, L. S., Staniszewska, A. D., Polanska, U. M., Cheraghchi-Bashi, A., Lawson, M., et al. (2018) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-17-0537 · Cited by 177
CDK4/6 Inhibitors Impair Recovery from Cytotoxic Chemotherapy in Pancreatic Adenocarcinoma
Salvador-Barbero, B., Álvarez-Fernández, M., Zapatero-Solana, E., El Bakkali, A., Menéndez, M. D. C., López-Casas, P. P., Di Domenico, T., Xie, T., VanArsdale, T., Shields, D. J., et al. (2020) · Cancer Cell · doi:10.1016/j.ccell.2020.01.007 · Cited by 176
Self-citationCells Lacking the RB1 Tumor Suppressor Gene Are Hyperdependent on Aurora B Kinase for Survival
Oser, M. G., Fonseca, R., Chakraborty, A. A., Brough, R., Spektor, A., Jennings, R. B., Flaifel, A., Novak, J. S., Gulati, A., Buss, E., et al. (2019) · Cancer Discovery · doi:10.1158/2159-8290.cd-18-0389 · Cited by 173
Mao, P., Cohen, O., Kowalski, K. J., Kusiel, J. G., Buendia-Buendia, J. E., Cuoco, M. S., Exman, P., Wander, S. A., Waks, A. G., Nayar, U., et al. (2020) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-19-3958 · Cited by 171
Challenges in the management of advanced, ER-positive, HER2-negative breast cancer
Hart, C. D., Migliaccio, I., Malorni, L., Guarducci, C., Biganzoli, L., & Di Leo, A. (2015) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2015.99 · Cited by 169
Johnson, S. M., Torrice, C. D., Bell, J. F., Monahan, K. B., Jiang, Q., Wang, Y., Ramsey, M. R., Jin, J., Wong, K.-K., Su, L., et al. (2010) · Journal of Clinical Investigation · doi:10.1172/jci41402 · Cited by 168
Transient CDK4/6 inhibition protects hematopoietic stem cells from chemotherapy-induced exhaustion
He, S., Roberts, P. J., Sorrentino, J. A., Bisi, J., White, H. S., Tiessen, R. G., Makhuli, K. M., Wargin, W. A., Tadema, H., van Hoogdalem, E., et al. (2017) · Science Translational Medicine · doi:10.1126/scitranslmed.aal3986 · Cited by 167
Weiss, J. M., Csoszi, T., Maglakelidze, M., Hoyer, R. J., Beck, J. T., Domine Gomez, M., Lowczak, A., Aljumaily, R., Rocha Lima, C. M., Boccia, R. V., et al. (2019) · Annals of Oncology · doi:10.1093/annonc/mdz278 · Cited by 165
CDK4/6 inhibition antagonizes the cytotoxic response to anthracycline therapy
McClendon, A. K., Dean, J. L., Rivadeneira, D. B., Yu, J. E., Reed, C. A., Gao, E., Farber, J. L., Force, T., Koch, W. J., & Knudsen, E. S. (2012) · Cell Cycle · doi:10.4161/cc.21127 · Cited by 163
Caldon, C. E., Sergio, C. M., Kang, J., Muthukaruppan, A., Boersma, M. N., Stone, A. M., Barraclough, J., Lee, C. S., Black, M. A., Miller, L. D., et al. (2012) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-11-0963 · Cited by 159
Cornell, L., Wander, S. A., Visal, T. H., Wagle, N., & Shapiro, G. I. (2019) · Cell Reports · doi:10.1016/j.celrep.2019.02.023 · Cited by 149
Antonysamy, S., Pustilnik, A., Manglicmot, D., Froning, K., Weichert, K., & Wasserman, S. (2018) · Worldwide Protein Data Bank · doi:10.2210/pdb6c2r/pdb · Cited by 148
Regulation of PRMT5–MDM4 axis is critical in the response to CDK4/6 inhibitors in melanoma
AbuHammad, S., Cullinane, C. M., Martin, C., Bacolas, Z., Ward, T. A., Chen, H., Slater, A. A., Ardley, K., Kirby, L., Chan, K. T., et al. (2019) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1901323116 · Cited by 136
Selective degradation of CDK6 by a palbociclib based PROTAC
Rana, S., Bendjennat, M., Kour, S., King, H. M., Kizhake, S., Zahid, M., & Natarajan, A. (2019) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2019.03.035 · Cited by 135
Bisi, J., Sorrentino, J. A., Roberts, P. J., Tavares, F. X., & Strum, J. C. (2016) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-15-0775 · Cited by 134
Combined Inhibition of STAT3 and DNA Repair in Palbociclib-Resistant ER-Positive Breast Cancer
Kettner, N. M., Vijayaraghavan, S., Durak, M. G., Bui, T. N., Kohansal, M., Ha, M. J., Liu, B., Rao, X., Wang, J., Yi, M., et al. (2019) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-18-3274 · Cited by 133
MAPK Reliance via Acquired CDK4/6 Inhibitor Resistance in Cancer
de Leeuw, R., McNair, C. M., Schiewer, M. J., Neupane, N. P., Brand, L. J., Augello, M. A., Li, Z., Cheng, L. C., Yoshida, A., Courtney, S. M., et al. (2018) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-18-0410 · Cited by 131
Jeselsohn, R. M., Brown, N. E., Arendt, L. M., Klebba, I., Hu, M. G., Kuperwasser, C., & Hinds, P. W. (2010) · Cancer Cell · doi:10.1016/j.ccr.2009.11.024 · Cited by 130
MDM2 antagonists overcome intrinsic resistance to CDK4/6 inhibition by inducing p21
Vilgelm, A. E., Saleh, N., Shattuck-Brandt, R. L., Riemenschneider, K., Slesur, L., Chen, S., Johnson, C. A., Yang, J., Blevins, A., Yan, C. W., et al. (2019) · Science Translational Medicine · doi:10.1126/scitranslmed.aav7171 · Cited by 125
Tan, A. R., Wright, G. S., Thummala, A. R., Danso, M. A., POPOVIC, L. S., Pluard, T., Han, H. S., Vojnović, Ž., Vasev, N., Ma, L., et al. (2019) · The Lancet Oncology · doi:10.1016/s1470-2045(19)30616-3 · Cited by 125
Lee, M. S., Helms, T. L., Feng, N., Gay, J., Chang, Q. E., Tian, F., Wu, J. Y., Toniatti, C., Heffernan, T. P., Powis, G., et al. (2016) · Oncotarget · doi:10.18632/oncotarget.9153 · Cited by 123
Hashizume, R., Zhang, A., Mueller, S., Prados, M. D., Lulla, R. R., Goldman, S., Saratsis, A. M., Mazar, A. P., Stegh, A. H., Cheng, S., et al. (2016) · Neuro-Oncology · doi:10.1093/neuonc/now106 · Cited by 123
G1 cyclin-dependent kinases are sufficient to initiate DNA synthesis in quiescent human fibroblasts
Connell‐Crowley, L., Elledge, S. J., & Harper, J. W. (1998) · Current Biology · doi:10.1016/s0960-9822(98)70021-1 · Cited by 122
Synergistic Drug Combinations with a CDK4/6 Inhibitor in T-cell Acute Lymphoblastic Leukemia
Pikman, Y., Alexe, G., Roti, G., Conway, A. S., Furman, A. A., Lee, E. S., Place, A. E., Kim, S., Saran, C., Modiste, R., et al. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-2869 · Cited by 120
Heilmann, A. M., Perera, R. M., Ecker, V., Nicolay, B. N., Bardeesy, N., Benes, C. H., & Dyson, N. J. (2014) · Cancer Research · doi:10.1158/0008-5472.can-13-2923 · Cited by 119
Targeting cell cycle and hormone receptor pathways in cancer
Comstock, C. E. S., Augello, M. A., Goodwin, J. F., de Leeuw, R., Schiewer, M. J., Ostrander, W. F., Burkhart, R. A., McClendon, A. K., McCue, P. A., Trabulsi, E. J., et al. (2013) · Oncogene · doi:10.1038/onc.2013.83 · Cited by 119
Naz, S., Sowers, A. L., Choudhuri, R., Wissler, M. F., Gamson, J., Mathias, A., Cook, J. A., & Mitchell, J. B. (2018) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-17-3575 · Cited by 117
Croessmann, S., Formisano, L., Kinch, L. N., Ericsson, P. I. G., Sudhan, D. R., Nagy, R. J., Mathew, A., Bernicker, E., Cristofanilli, M., He, J., et al. (2018) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-18-1544 · Cited by 116
Combined CDK4/6 and mTOR Inhibition Is Synergistic against Glioblastoma via Multiple Mechanisms
Olmez, I., Brenneman, B. R., Xiao, A., Serbulea, V., Benamar, M., Zhang, Y., Manigat, L. C., Abbas, T., Lee, J., Nakano, I., et al. (2017) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-17-0803 · Cited by 114
CDK4 Amplification Reduces Sensitivity to CDK4/6 Inhibition in Fusion-Positive Rhabdomyosarcoma
Olanich, M. E., Sun, W., Hewitt, S. M., Abdullaev, Z., Pack, S., & Barr, F. G. (2015) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-14-2955 · Cited by 102
Sensitivity of KRAS-Mutant Colorectal Cancers to Combination Therapy That Cotargets MEK and CDK4/6
Ziemke, E. K., Dosch, J. S., Maust, J. D., Shettigar, A., Sen, A., Welling, T. H., Hardiman, K. M., & Sebolt, J. S. (2015) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-0829 · Cited by 102
Yu, J., Yan, J., Guo, Q., Chi, Z., Tang, B., Zheng, B., Yu, J., Yin, T., Cheng, Z., Wu, X., et al. (2019) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-19-0475 · Cited by 100
Inhibition of CDK4/6 protects against radiation-induced intestinal injury in mice
Liang, W., Leibowitz, B. J., Wang, X., Epperly, M. W., Greenberger, J. S., Zhang, L., & Yu, J. (2016) · Journal of Clinical Investigation · doi:10.1172/jci88410 · Cited by 99
Romano, G., Chen, P.-L., Song, P., McQuade, J. L., Liang, R. J., Liu, M., Roh, W., Duose, D. Y., Carapeto, F. C. L., Li, J., et al. (2018) · Cancer Discovery · doi:10.1158/2159-8290.cd-17-0745 · Cited by 96
Knudsen, E. S., Kumarasamy, V. M., Chung, S., Ruiz, A., Vail, P. J., Tzetzo, S. L., Wu, J., Nambiar, R., Sivinski, J., Chauhan, S. S., et al. (2020) · Gut · doi:10.1136/gutjnl-2020-321000 · Cited by 94
Nasmyth, K. (2001) · Cell · doi:10.1016/s0092-8674(01)00604-3 · Cited by 93
Combined CDK4/6 and Pan-mTOR Inhibition Is Synergistic Against Intrahepatic Cholangiocarcinoma
Song, X., Liu, X., Wang, H., Wang, J., Qiao, Y., Cigliano, A., Utpatel, K., Ribback, S., Pilo, M. G., Serra, M., et al. (2018) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-18-0284 · Cited by 88
Pek, M., Yatim, S. M. J. M., Chen, Y., Li, J., Gong, M., Jiang, X., Zhang, F., Zheng, J., Wu, X., & Yu, Q. (2017) · Oncogene · doi:10.1038/onc.2017.120 · Cited by 86
Long, F., He, Y., Fu, H., Li, Y., Bao, X., Wang, Q., Wang, Y., Xie, C., & Lou, L. (2019) · Cancer Science · doi:10.1111/cas.13957 · Cited by 86
Definition of PKC-α, CDK6, and MET as Therapeutic Targets in Triple-Negative Breast Cancer
Hsu, Y.-H., Yao, J., Chan, L.-C., Wu, T.-J., Hsu, J. L., Fang, Y., Wei, Y., Wu, Y., Huang, W.-C., Liu, C., et al. (2014) · Cancer Research · doi:10.1158/0008-5472.can-14-0584 · Cited by 80
CDK4/6 or MAPK blockade enhances efficacy of EGFR inhibition in oesophageal squamous cell carcinoma
Zhou, J. R., Wu, Z., Wong, G. S., Pectasides, E., Nagaraja, A. K., Stachler, M. D., Zhang, H., Chen, T., Zhang, H., Liu, J. B., et al. (2017) · Nature Communications · doi:10.1038/ncomms13897 · Cited by 80
CDK6 protects epithelial ovarian cancer from platinum‐induced death via FOXO3 regulation
Dall’Acqua, A., Sonego, M., Pellizzari, I., Pellarin, I., Canzonieri, V., D’Andrea, S., Benevol, S., Sorio, R., Giorda, G., Califano, D., et al. (2017) · EMBO Molecular Medicine · doi:10.15252/emmm.201607012 · Cited by 80
CDK4 phosphorylation status and a linked gene expression profile predict sensitivity to palbociclib
Raspé, E., Coulonval, K., Pita, J. M. G., Paternot, S., Rothé, F., Twyffels, L., Brohée, S., Craciun, L., Larsimont, D., Kruys, V., et al. (2017) · EMBO Molecular Medicine · doi:10.15252/emmm.201607084 · Cited by 77
CDK6 Antagonizes p53-Induced Responses during Tumorigenesis
Bellutti, F., Tigan, A.-S., Nebenfuehr, S., Dolezal, M., Zojer, M., Grausenburger, R., Hartenberger, S., Kollmann, S., Doma, E., Prchal‐Murphy, M., et al. (2018) · Cancer Discovery · doi:10.1158/2159-8290.cd-17-0912 · Cited by 77
Self-citationPatel, P. M., Tsiperson, V., Gottesman, S. R. S., Somma, J., & Blain, S. W. (2018) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-17-0602 · Cited by 74
Teh, J. L. F., Cheng, P. F., Purwin, T. J., Nikbakht, N., Patel, P. S., Chervoneva, I., Ertel, A., Fortina, P. M., Kleiber, I., HooKim, K., et al. (2018) · Cancer Discovery · doi:10.1158/2159-8290.cd-17-0699 · Cited by 74
Liu, C., Lau, K.-Y., Hsu, C., Chen, J.-L., Lee, C.-H., Huang, T., Chen, Y., Huang, C.-T., Lin, P., & Tseng, L. (2017) · PLoS ONE · doi:10.1371/journal.pone.0189007 · Cited by 68
Combined c-Met/Trk Inhibition Overcomes Resistance to CDK4/6 Inhibitors in Glioblastoma
Olmez, I., Zhang, Y., Manigat, L. C., Benamar, M., Brenneman, B. R., Nakano, I., Godlewski, J. A., Bronisz, A., Lee, J., Abbas, T., et al. (2018) · Cancer Research · doi:10.1158/0008-5472.can-17-3124 · Cited by 68
CDK4/6 inhibition mitigates stem cell damage in a novel model for taxane‐induced alopecia
Purba, T. S., Ng’andu, K., Brunken, L., Smart, E., Mitchell, E., Hassan, N. M. K. N., O'Brien, A., Mellor, C. E. L., Jackson, J., Shahmalak, A., et al. (2019) · EMBO Molecular Medicine · doi:10.15252/emmm.201911031 · Cited by 66
Rubio, C., Martínez‐Fernández, M., Segovia, C., Lodewijk, I., Suárez-Cabrera, C., Segrelles, C., López-Calderón, F., Munera-Maravilla, E., Santos, M., Bernardini, A., et al. (2018) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-18-0685 · Cited by 64
Bisi, J., Sorrentino, J. A., Jordan, J. L., Darr, D. D., Roberts, P. J., Tavares, F. X., & Strum, J. C. (2017) · Oncotarget · doi:10.18632/oncotarget.16216 · Cited by 62
Foidart, P., Yip, C., Radermacher, J., Blacher, S., Liénard, M., Montero‐Ruiz, L., Maquoi, E., Montaudon, É., Château‐Joubert, S., Collignon, J., et al. (2018) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-18-1880 · Cited by 58
A Functional Landscape of Resistance to MEK1/2 and CDK4/6 Inhibition in NRAS-Mutant Melanoma
Hayes, T. K., Luo, F., Cohen, O., Goodale, A. B., Lee, Y., Pantel, S., Bagul, M., Piccioni, F., Root, D. E., Garraway, L. A., et al. (2019) · Cancer Research · doi:10.1158/0008-5472.can-18-2711 · Cited by 51
Combination Paclitaxel and Palbociclib: Results of a Phase I Trial in Advanced Breast Cancer
Clark, A. S., McAndrew, N. P., Troxel, A. B., Feldman, M. D., Lal, P., Rosen, M. A., Burrell, J. A., Redlinger, C., Gallagher, M., Bradbury, A. R., et al. (2019) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-18-0790 · Cited by 49
SLC36A1-mTORC1 signaling drives acquired resistance to CDK4/6 inhibitors
Yoshida, A., Bu, Y., Qie, S., Wrangle, J. M., Camp, E. R., Hazard, E. S., Hardiman, G., de Leeuw, R., Knudsen, K. E., & Diehl, J. A. (2019) · Science Advances · doi:10.1126/sciadv.aax6352 · Cited by 47
Direct CDKN2 Modulation of CDK4 Alters Target Engagement of CDK4 Inhibitor Drugs
Green, J. L., Okerberg, E. S., Sejd, J. R., Palafox, M., Monserrat, L., Alemayehu, S., Wu, J., Sykes, M., Aban, A., Serra, V., et al. (2019) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-18-0755 · Cited by 43
Gao, Y., Shen, J. K., Choy, E., Mankin, H. J., Hornicek, F. J., & Duan, Z. (2017) · Cellular Oncology · doi:10.1007/s13402-017-0316-x · Cited by 41
Cao, J. Q., Zhu, Z., Wang, H., Nichols, T. C., Lui, G. Y. L., Deng, S., Rejto, P. A., VanArsdale, T. L., Hardwick, J. S., Weinrich, S. L., et al. (2019) · Oncogene · doi:10.1038/s41388-019-0708-7 · Cited by 41
CDK4/6 Therapeutic Intervention and Viable Alternative to Taxanes in CRPC
Stice, J. P., Wardell, S. E., Norris, J. D., Yllanes, A. P., Alley, H. M., Haney, V. O., White, H. S., Safi, R., Winter, P. S., Cocce, K. J., et al. (2017) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-17-0028 · Cited by 40
Kumarasamy, V. M., Ruiz, A., Nambiar, R., Witkiewicz, A. K., & Knudsen, E. S. (2019) · Oncogene · doi:10.1038/s41388-019-1102-1 · Cited by 39
Cytoplasmic Cyclin E Mediates Resistance to Aromatase Inhibitors in Breast Cancer
Doostan, I., Karakaş, C., Kohansal, M., Low, K.-H., Ellis, M. J., Olson, J. A., Suman, V. J., Hunt, K. K., Moulder, S., & Keyomarsi, K. (2017) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-17-1544 · Cited by 38
Yu, Z., He, S., Wang, D., Patel, H., Miller, C. P., Brown, J. L., Hattersley, G., & Saeh, J. C. (2017) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-17-0670 · Cited by 36
Tong, Z., Sathe, A., Ebner, B., Pan, Q., Veltkamp, C., Gschwend, J. E., Holm, P. S., & Nawroth, R. (2019) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-019-1322-9 · Cited by 36
Ribociclib Plus Trastuzumab in Advanced HER2-Positive Breast Cancer: Results of a Phase 1b/2 Trial
Goel, S., Pernas, S., Tan‐Wasielewski, Z., Barry, W. T., Bardia, A., Rees, R., Andrews, C., Tahara, R. K., Trippa, L., Mayer, E. L., et al. (2019) · Clinical Breast Cancer · doi:10.1016/j.clbc.2019.05.010 · Cited by 35
CDK4/6 Inhibitors: What Is the Best Cocktail?
Malumbres, M. (2018) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-18-2177 · Cited by 34
Self-citationGottesman, S. R. S., Somma, J., Tsiperson, V., Dresner, L., Govindarajulu, U. S., Patel, P. M., & Blain, S. W. (2018) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-18-0188 · Cited by 15
CDK4/6 Inhibitors resTORe Therapeutic Sensitivity in HER2 + Breast Cancer
Malumbres, M. (2016) · Cancer Cell · doi:10.1016/j.ccell.2016.02.016 · Cited by 14
Self-citationLin, S., Zhao, X., Li, T., Zhang, H., Tan, H., Wang, X., Jiang, L., Liu, Y., Sun, J., Linghu, L., et al. (2019) · Cancer Research · doi:10.1158/1538-7445.am2019-4425 · Cited by 11
Palbociclib and Fulvestrant in Breast Cancer
Naik, R. D., Batra, A., & Gupta, V. G. (2019) · New England Journal of Medicine · doi:10.1056/nejmc1816595 · Cited by 5
Cited by
Matthews, H. K., Bertoli, C., & de Bruin, R. A. M. (2022) · Nature Reviews Molecular Cell Biology · doi:10.1038/s41580-021-00404-3 · Cited by 1,506
Targeting cell-cycle machinery in cancer
Suski, J. M., Braun, M., Strmiska, V., & Sicinski, P. (2021) · Cancer Cell · doi:10.1016/j.ccell.2021.03.010 · Cited by 564
Targeting CDK4 and CDK6 in cancer
Goel, S., Bergholz, J. S., & Zhao, J. J. (2022) · Nature Reviews Cancer · doi:10.1038/s41568-022-00456-3 · Cited by 531
CDK4 and CDK6 kinases: From basic science to cancer therapy
Fassl, A., Geng, Y., & Sicinski, P. (2022) · Science · doi:10.1126/science.abc1495 · Cited by 464
Proteolysis-targeting chimeras (PROTACs) in cancer therapy
Li, X., Pu, W., Zheng, Q., Ai, M., Chen, S., & Peng, Y. (2022) · Molecular Cancer · doi:10.1186/s12943-021-01434-3 · Cited by 337
Metadata
- Authors
- Álvarez-Fernández, M., & Malumbres, M.
- Venue
- Cancer Cell
- Publisher
- Elsevier BV
- Published
- 2020-04
- Volume
- 37
- Issue
- 4
- Pages
- 514-529
- ISSN
- 1535-6108 (ISSN-L)
- OpenAlex
- W3016055296
- Cited by
- 390
- References
- 137
- FWCI
- 24.01
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.